TRIUMPH-4 is the first Phase 3 readout for retatrutide. Published in December 2025, the trial enrolled 445 adults with obesity and knee osteoarthritis. At 68 weeks, participants on retatrutide achieved 28.7% mean weight loss, meeting the primary endpoint and all key secondary endpoints. This is the largest weight loss ever reported in a Phase 3 pharmaceutical trial.
For context: semaglutide (Wegovy) achieved 14.9% in STEP-1. Tirzepatide (Zepbound) achieved 20.9% in SURMOUNT-1. Retatrutide's 28.7% is not an incremental improvement. It is a step change that redefines the ceiling for what pharmacotherapy can achieve in obesity.
Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GIP and GLP-1). Retatrutide activates three: GIP, GLP-1, and the glucagon receptor. The glucagon component is the mechanistic advance that explains the weight loss gap.
Glucagon receptor activation increases hepatic energy expenditure through thermogenesis and glycogenolysis. It promotes lipolysis in adipose tissue through distinct pathways from GLP-1. It reduces hepatic fat accumulation through mechanisms additive to, not redundant with, the incretin pathway. The Phase 2a MASLD substudy demonstrated greater than 90% liver fat normalization at the highest dose in 48 weeks.
The concern with glucagon receptor agonism has always been hyperglycemia. Glucagon raises blood glucose. The engineering solution in retatrutide is that the concurrent GIP and GLP-1 agonism provides sufficient insulin stimulation and glucagon suppression to offset the hyperglycemic risk. In the Phase 2 diabetes trial (n=281), retatrutide achieved 77 to 82% euglycemia and reduced HbA1c substantially, confirming that the glucose-raising effect of glucagon is managed by the dual incretin component.
TRIUMPH-4 was not a pure obesity trial. It enrolled adults with obesity and symptomatic knee osteoarthritis. The primary weight loss endpoint was met (28.7%), but the secondary osteoarthritis endpoints are equally significant: 75.8% reduction in WOMAC pain scores, with substantial improvements in physical function and stiffness.
This matters because obesity and osteoarthritis form a self-reinforcing cycle. Excess weight accelerates joint degeneration. Joint pain limits physical activity. Limited activity promotes further weight gain. A single compound that breaks both sides of this cycle simultaneously has clinical value beyond either outcome alone.
TRIUMPH-4 is one of eight Phase 3 trials in the TRIUMPH program. The remaining seven cover obesity without comorbidity, type 2 diabetes, obstructive sleep apnea, chronic low back pain, cardiovascular outcomes, renal outcomes, and MASLD. Over 5,800 participants across 13 countries are enrolled. Readouts are expected throughout 2026.
If the remaining data confirms what TRIUMPH-4 and the Phase 2 program suggest, retatrutide will be the most effective pharmaceutical weight loss agent ever developed, with demonstrated benefit across metabolic, musculoskeletal, hepatic, and potentially cardiovascular and renal domains.
Retatrutide is not available. It is not approved by any regulatory authority. It cannot be legally obtained outside of clinical trial enrollment. It is not a research peptide sold by vendors. Anyone selling retatrutide outside of a clinical trial is selling an unverified, unregulated substance.
The earliest possible FDA approval, assuming positive remaining TRIUMPH data and priority review, would be late 2027 at the earliest. This is a compound to watch, not a compound to buy.
Retatrutide's 28.7% weight loss in TRIUMPH-4 establishes a new benchmark that exceeds both semaglutide (14.9%, STEP-1) and tirzepatide (20.9%, SURMOUNT-1) by clinically meaningful margins. The triple agonist mechanism provides a plausible pharmacological explanation for the improvement. Seven additional Phase 3 readouts in 2026 will determine whether this single-trial result generalizes across populations and indications. The data so far is the most compelling obesity pharmacotherapy result in the literature.
Every Tuesday: one landmark study, one protocol, one regulatory update. Plus new research posts as they publish. Free.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use